Free Trial

DocGo (DCGO) Competitors

DocGo logo
$0.68 +0.01 (+1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$0.68 +0.00 (+0.18%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DCGO vs. LFMD, AIRS, BNR, NAKA, and BDSX

Should you be buying DocGo stock or one of its competitors? The main competitors of DocGo include LifeMD (LFMD), AirSculpt Technologies (AIRS), Burning Rock Biotech (BNR), KindlyMD (NAKA), and Biodesix (BDSX). These companies are all part of the "healthcare" industry.

How does DocGo compare to LifeMD?

LifeMD (NASDAQ:LFMD) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

LifeMD has a net margin of 6.58% compared to DocGo's net margin of -56.61%. DocGo's return on equity of -34.41% beat LifeMD's return on equity.

Company Net Margins Return on Equity Return on Assets
LifeMD6.58% -83.93% -7.85%
DocGo -56.61%-34.41%-23.82%

In the previous week, LifeMD had 1 more articles in the media than DocGo. MarketBeat recorded 4 mentions for LifeMD and 3 mentions for DocGo. DocGo's average media sentiment score of 1.09 beat LifeMD's score of 0.15 indicating that DocGo is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LifeMD
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DocGo
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

LifeMD has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LifeMD$194.05M1.26$14.35M$0.2619.73
DocGo$322.20M0.21-$182.40M-$1.85N/A

35.5% of LifeMD shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 18.4% of LifeMD shares are held by insiders. Comparatively, 3.8% of DocGo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LifeMD currently has a consensus target price of $9.14, suggesting a potential upside of 78.22%. DocGo has a consensus target price of $2.38, suggesting a potential upside of 247.32%. Given DocGo's higher probable upside, analysts plainly believe DocGo is more favorable than LifeMD.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LifeMD
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
DocGo
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

LifeMD has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, DocGo has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Summary

LifeMD beats DocGo on 10 of the 15 factors compared between the two stocks.

How does DocGo compare to AirSculpt Technologies?

AirSculpt Technologies (NASDAQ:AIRS) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

AirSculpt Technologies currently has a consensus target price of $6.00, suggesting a potential upside of 70.45%. DocGo has a consensus target price of $2.38, suggesting a potential upside of 247.32%. Given DocGo's stronger consensus rating and higher probable upside, analysts plainly believe DocGo is more favorable than AirSculpt Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AirSculpt Technologies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
DocGo
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

91.5% of AirSculpt Technologies shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 44.6% of AirSculpt Technologies shares are held by insiders. Comparatively, 3.8% of DocGo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AirSculpt Technologies has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, DocGo has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

In the previous week, DocGo had 1 more articles in the media than AirSculpt Technologies. MarketBeat recorded 3 mentions for DocGo and 2 mentions for AirSculpt Technologies. DocGo's average media sentiment score of 1.09 beat AirSculpt Technologies' score of 0.00 indicating that DocGo is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AirSculpt Technologies
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DocGo
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

AirSculpt Technologies has a net margin of -7.68% compared to DocGo's net margin of -56.61%. AirSculpt Technologies' return on equity of -5.01% beat DocGo's return on equity.

Company Net Margins Return on Equity Return on Assets
AirSculpt Technologies-7.68% -5.01% -2.19%
DocGo -56.61%-34.41%-23.82%

AirSculpt Technologies has higher earnings, but lower revenue than DocGo. AirSculpt Technologies is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AirSculpt Technologies$151.82M1.64-$11.67M-$0.19N/A
DocGo$322.20M0.21-$182.40M-$1.85N/A

Summary

AirSculpt Technologies beats DocGo on 9 of the 15 factors compared between the two stocks.

How does DocGo compare to Burning Rock Biotech?

DocGo (NASDAQ:DCGO) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

DocGo presently has a consensus target price of $2.38, indicating a potential upside of 247.32%. Given DocGo's stronger consensus rating and higher probable upside, equities research analysts clearly believe DocGo is more favorable than Burning Rock Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DocGo
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29
Burning Rock Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

56.4% of DocGo shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 3.8% of DocGo shares are owned by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

DocGo has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Burning Rock Biotech has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.

In the previous week, DocGo had 2 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for DocGo and 1 mentions for Burning Rock Biotech. DocGo's average media sentiment score of 1.09 beat Burning Rock Biotech's score of 0.95 indicating that DocGo is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DocGo
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Burning Rock Biotech
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Burning Rock Biotech has a net margin of -10.27% compared to DocGo's net margin of -56.61%. Burning Rock Biotech's return on equity of -9.98% beat DocGo's return on equity.

Company Net Margins Return on Equity Return on Assets
DocGo-56.61% -34.41% -23.82%
Burning Rock Biotech -10.27%-9.98%-6.69%

Burning Rock Biotech has lower revenue, but higher earnings than DocGo. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DocGo$322.20M0.21-$182.40M-$1.85N/A
Burning Rock Biotech$77.16M2.37-$7.92M-$0.79N/A

Summary

Burning Rock Biotech beats DocGo on 8 of the 15 factors compared between the two stocks.

How does DocGo compare to KindlyMD?

DocGo (NASDAQ:DCGO) and KindlyMD (NASDAQ:NAKA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

56.4% of DocGo shares are owned by institutional investors. 3.8% of DocGo shares are owned by company insiders. Comparatively, 24.5% of KindlyMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

DocGo has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, KindlyMD has a beta of 17.12, meaning that its share price is 1,612% more volatile than the S&P 500.

KindlyMD has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DocGo$322.20M0.21-$182.40M-$1.85N/A
KindlyMD$1.82M73.93-$52.23M-$0.87N/A

DocGo has a net margin of -56.61% compared to KindlyMD's net margin of -2,866.57%. KindlyMD's return on equity of -16.11% beat DocGo's return on equity.

Company Net Margins Return on Equity Return on Assets
DocGo-56.61% -34.41% -23.82%
KindlyMD -2,866.57%-16.11%-11.25%

In the previous week, DocGo had 2 more articles in the media than KindlyMD. MarketBeat recorded 3 mentions for DocGo and 1 mentions for KindlyMD. DocGo's average media sentiment score of 1.09 beat KindlyMD's score of 1.02 indicating that DocGo is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DocGo
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
KindlyMD
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DocGo presently has a consensus price target of $2.38, indicating a potential upside of 247.32%. KindlyMD has a consensus price target of $0.75, indicating a potential upside of 284.62%. Given KindlyMD's stronger consensus rating and higher possible upside, analysts plainly believe KindlyMD is more favorable than DocGo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DocGo
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29
KindlyMD
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

KindlyMD beats DocGo on 9 of the 14 factors compared between the two stocks.

How does DocGo compare to Biodesix?

Biodesix (NASDAQ:BDSX) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Biodesix has a net margin of -33.26% compared to DocGo's net margin of -56.61%. DocGo's return on equity of -34.41% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Biodesix-33.26% -1,760.83% -36.32%
DocGo -56.61%-34.41%-23.82%

In the previous week, Biodesix had 5 more articles in the media than DocGo. MarketBeat recorded 8 mentions for Biodesix and 3 mentions for DocGo. DocGo's average media sentiment score of 1.09 beat Biodesix's score of 0.25 indicating that DocGo is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biodesix
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
DocGo
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biodesix currently has a consensus price target of $33.00, indicating a potential upside of 120.88%. DocGo has a consensus price target of $2.38, indicating a potential upside of 247.32%. Given DocGo's higher probable upside, analysts plainly believe DocGo is more favorable than Biodesix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biodesix
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
DocGo
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

Biodesix has higher earnings, but lower revenue than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biodesix$88.50M1.71-$35.26M-$4.06N/A
DocGo$322.20M0.21-$182.40M-$1.85N/A

21.0% of Biodesix shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 23.2% of Biodesix shares are held by insiders. Comparatively, 3.8% of DocGo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Biodesix has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, DocGo has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.

Summary

DocGo beats Biodesix on 8 of the 15 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Sign up to receive the latest news and ratings for DCGO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DCGO vs. The Competition

MetricDocGoMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$66.85M$8.11B$6.24B$11.86B
Dividend YieldN/A2.18%2.73%5.21%
P/E RatioN/A24.8429.0428.48
Price / Sales0.2117.51477.1060.43
Price / Cash12.2313.2327.6236.52
Price / Book0.534.949.676.67
Net Income-$182.40M$183.43M$3.55B$332.64M
7 Day Performance-4.91%0.20%1.70%2.01%
1 Month Performance19.96%5.27%5.62%9.19%
1 Year Performance-70.90%0.38%34.42%39.59%

DocGo Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DCGO
DocGo
3.7839 of 5 stars
$0.68
+1.0%
$2.38
+247.3%
N/A$66.85M$322.20MN/A3,568
LFMD
LifeMD
4.217 of 5 stars
$4.98
+6.3%
$9.14
+83.8%
N/A$239.13M$194.05M19.17230
AIRS
AirSculpt Technologies
2.1271 of 5 stars
$3.31
+23.3%
$6.00
+81.5%
N/A$232.45M$151.82MN/A240
BNR
Burning Rock Biotech
1.4576 of 5 stars
$17.44
+2.6%
N/AN/A$187.65M$77.16MN/A1,390
NAKA
KindlyMD
4.1298 of 5 stars
$0.19
+9.9%
$0.75
+287.6%
N/A$133.52M$1.82MN/AN/A

Related Companies and Tools


This page (NASDAQ:DCGO) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners